Cumberland Pharmaceuticals Inc (CPIX)

Healthcare Drug Manufacturers - Specialty & Generic

6.70 $

-0.7% vs. previous close

Closing price · As of: 31. Jul 2026

Add to watchlist

Stock Watch

Stock Watch will tell you what changes at Cumberland Pharmaceuticals Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 11 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet

U/D Accumulation

Breakout & Setup

Bullish Reversal Bar

Momentum & Trend

21-EMA Trend Above the 50- & 200-SMA High ADR (≥5%) Mark Minervini: Trend Criteria — 1 Month Power Trend Qullamaggie: Trend Intensity (13/65) Richard Moglen: Top Performers 3/6 Month Stan Weinstein: Checklist Stan Weinstein: Stage 2

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Basics

Market Cap

0.1$B

Shares Outstanding

15Mio.

Float

58.4%

Beta

0.1

Performance

Perf. 1M

14.40%

Perf. 3M

122.80%

Perf. 6M

62.90%

YTD Performance (%)

46.50%

52-Week-High Distance

-9.8%

Perf. 1Y

53.94%

Perf. 3Y

93.60%

Perf. 5Y

95.16%

Valuation

P/E

–

Forward P/E

50.0

PEG

1.7

P/B

6.7

P/S

3.1

EV/EBITDA

22.5

Price/FCF

93.6

Profitability

Gross Margin

82.9%

EBIT Margin

–

Net Margin

-17.6%

Return on Equity

-29.8%

Return on Assets

-6.4%

Balance Sheet & Safety

Equity Ratio

–

Debt/Equity

0.5

Altman Z″

1.53

Piotroski

4 out of 9

Growth

Sales Growth Last Quarter

-22.00%

EPS Growth Last Quarter

0.00%

Sales Growth (Year)

17.57%

Forward Sales Growth

24.60%

Forward EPS Growth

55.60%

Dividend

Dividend Yield

22.39%

Dividend Per Share (TTM)

1.50$

Payout Ratio

0.0%

Years Without a Cut

0Years

Increase Streak

0Years

Quality & Screener

Stage

RS Rating

EPS Rating

Piotroski

4 out of 9

Fundamental Rating

D (34 out of 100)

Altman Z″

1.53

AI Rating

–

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Analysts & Price Target

Current Price 6.70 $

Price Target (average) 8.50 $

The price target sits 26.9% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

4. Aug 2026 · after the close · Q2 2026

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

From To Indexed

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter	EPS (Earnings Per Share)	EPS YoY (%)	Sales ($M)	Sales YoY (%)	Net Margin (%)	OCF ($M)	FCF ($M)
2024: Q4	-0.13	–	10	11.60	-18.20	2	2
2025: Q1	0.08	–	12	37.80	10.70	4	4
2025: Q2	-0.05	–	11	10.00	-6.80	1	1
2025: Q3	-0.13	–	8	-8.70	-23.40	0	0
2025: Q4	-0.09	–	14	31.10	-10.30	0	0
2026: Q1	-0.21	-349.60	9	-22.00	-34.40	0	0

What Do These Terms Mean?

EPS (Earnings Per Share):: Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):: Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:: All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:: What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):: The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):: Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Cumberland Pharmaceuticals Inc., ein Spezialpharmaunternehmen, konzentriert sich auf den Erwerb, die Entwicklung und die Vermarktung verschreibungspflichtiger Produkte.

Employees	93
Headquarters	Nashville, TN
Website	cumberlandpharma.com
IPO Date	11. Aug 2009

Management

Management
Name	Title	Birth Year
A. J. Kazimi MBA	Founder, Chairman, President & CEO	1958
John Michael Hamm C.M.A.	Vice President Accounting & Finance and CFO	1956
James Lowrance Herman	VP of Trade & Distribution and Chief Compliance Officer	1955
Christopher T. Bitterman	Vice President of Sales & Marketing	1965
Todd M. Anthony	Vice President of Organizational Development	1961
Adam S. Mostafa	Managing Director of Banking & Investor Relations	1980

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.